MedTrace Logo

Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

NCT04862962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-03-02

No results posted yet for this study

Summary

Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.

Conditions

  • Dyslipidemias

Interventions

DRUG

Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose

Oral Tablets 10 mg/10 mg or 20 mg/10 mg

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Joel Rodriguez Saldaña, M.D · Resultados Médicos, desarrollo e Investigación

  • Francisco G Padilla Padilla, M.D · Independent

  • Ernesto G Cardona Muñoz, M.D · Independent

  • David Cardona Müller, M.D · Independent

  • Marcos Ibarra Flores, M.D · Cardiólogos Certificados S.C

  • José A Estrada Suarez, M.D · Independent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-01-15
Completion
2022-02-15

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04862962 on ClinicalTrials.gov